Results 351 to 360 of about 276,777 (390)

Diagnosis and Management of Type 2 Acute Coronary Syndrome in Patients Without Pre-existing Cardiomyopathy in Centers With and Without Percutaneous Coronary Intervention. [PDF]

Cureus
Fournier V, Nazeyrollas P, Lefebvre C, Metz D, Faroux L.   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

D-dimer/high-sensitivity troponin I ratio in the diagnosis of acute pulmonary embolism and/or non-ST-elevation myocardial infarction. [PDF]

Medicine (Baltimore)
Sahin A, Avci A, Cinar H, Aksay E, Simsek Y, Tatar SD, Gok MY, Yildirim O, Yildirim A, Yolcu S, Yesiloglu O, Diken OE, Avci BS.   +12 more
europepmc   +1 more source

Matrix metalloproteinase inhibition protects against junctophilin‐2 proteolysis during doxorubicin‐induced cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Treatment of cancer patients with anthracyclines is known to cause dose‐dependent cardiotoxicity through several mechanisms including enhanced oxidative stress, ultimately resulting in defective excitation–contraction coupling.
Wesam Bassiouni, Brandon Y. H. Chan, Andrej Roczkowsky, Joshua W. Kranrod, Zabed Mahmud, Joseph O. Primeau, Woo Jung Cho, Howard S. Young, John M. Seubert, Richard Schulz   +9 more
wiley   +1 more source

Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases. [PDF]

RMD Open
Adjailia EB, Grasshoff H, Schinke S, Fourlakis K, Jendrek ST, Lamprecht P, Riemekasten G, Humrich JY.   +7 more
europepmc   +1 more source

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection. Experimental Approach Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure ...
Jort S. A. van der Geest, Ilse R. Kelters, Bauke Arends, Willem B. van Ham, Ernest Diez Benavente, Thirza A. Lapré, Petra van der Kraak, Pim van der Harst, Arco J. Teske, Andreas Dendorfer, M. Mostafa Mokhles, Pieter A. Doevendans, Teun P. de Boer, Linda W. van Laake, Joost P. G. Sluijter, Vasco Sampaio‐Pinto   +15 more
wiley   +1 more source

Prognostic value of cardiac biomarkers in surgery for acute type A aortic dissection: mid-term follow-up results. [PDF]

J Thorac Dis
Zhou S, Liu Y, Zhang B, Wang L, Xie M, Wang H, Sun X.   +6 more
europepmc   +1 more source

Myocardial injury in patients with acute ischemic stroke: Prevalence and types of triggers of myocardial demand ischemia. [PDF]

Eur Stroke J
Stengl H, Böhme S, Richter O, Hellwig S, Klammer MG, Ganeshan R, Reimann L, Lieschke S, von Rennenberg R, Audebert HJ, Doehner W, Nolte CH, Endres M, Scheitz JF.   +13 more
europepmc   +1 more source

Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy [PDF]

, 2017
Canter, Charles, et al,
core   +1 more source

Can Systemic Inflammatory Markers Be Used in Pulmonary Embolism Risk Assessment in Patients with Acute Pulmonary Thromboembolism? [PDF]

J Inflamm Res
Özdemir L, Özdemir B, Gegin S, Aksu EA, Pazarlı AC.   +4 more
europepmc   +1 more source